Alpha Crest Capital Management LLC Chemo Centryx, Inc. Transaction History

Alpha Crest Capital Management LLC

$0
Q4 2022

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 11, 2022	BUY	$15.36 - $27.51 $217,912 - $390,284	14,187 Added 126.65%	25,389 $629,000
Q1 2022 May 12, 2022	SELL	$22.22 - $39.12 $64,393 - $113,369	-2,898 Reduced 20.55%	11,202 $281,000
Q4 2021 Feb 09, 2022	BUY	$18.38 - $40.5 $259,158 - $571,050	14,100 New	14,100 $513,000
Q3 2021 Nov 10, 2021	SELL	$13.18 - $19.83 $302,072 - $454,483	-22,919 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$9.59 - $50.88 $95,123 - $504,678	9,919 Added 76.3%	22,919 $307,000
Q1 2021 May 13, 2021	BUY	$49.53 - $68.4 $643,890 - $889,200	13,000 New	13,000 $666,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Crest Capital Management LLC with notifications on news.